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Synthesis and evaluation of antitumor activity 
of new 4-substituted thieno[3,2-d]pyrimidine and 
thienotriazolopyrimidine derivatives 
3-Methyl-6-phenyl-2-thioxo-2,3-dihydrothieno[3,2-d]pyrimi-
din-4(1H)-one (2), on treatment with phosphorous oxychoride, 
affored 4-chloro-3-methyl-6-phenyl -thieno[3,2-d]pyrimidine-
2(3H)-thione (3). A series of novel 6-phenyl-thieno[3,2-d]py-
rimidine derivatives 4-9 bearing different functional groups 
were synthesized via treatment of compound 3 with different 
reagents. On the other hand, compound 2 was used to synthe-
size ethyl-[(3-methyl-6-phenyl-2-thioxo-2,3-dihydro-
thieno[3,2-d]pyrimidin-4-yl)-oxy]acetate (10), 2-hydrazinyl- 
-3-methyl-6-phenyl-thieno[3,2-d]pyrimidin-4(3H)-one (11), 
3-methyl-2-(methyl-sulfanyl)-6-phenyl-thieno[3,2-d]pyrimi-
din-4(3H)-one (12) and N-(phenyl)/4-chlorophenyl or me-
thoxy-phenyl)-2-[(3-methyl-4-oxo-6-phenyl-3,4-dihydro-
thieno[3,2-d]pyrimidin-2-yl)-sulfanyl]-acetamide (13a-c). In 
addition, compound 12 was used to synthesize thieno[1,2,4]
triazolopyrimidine derivatives 14 and 15 and 3-methyl- 
-2-(methyl-sulfonyl)-6-phenyl-thieno[3,2-d]pyrimidin-4(3H)- 
-one (16) through the reaction with the respective reagents. 
Moreover, the reaction of 16 with 4-phenylenediamine gave 
2-[(4-aminophenyl)-amino]-3-methyl-6-phenyl-thieno[3,2-d]
pyrimidin-4(3H)-one (17), which reacted with methanesulfo-
nyl chloride to afford N-{4-[(3-methyl-4-oxo-6-phenyl-3H,4H- 
-thieno[3,2-d]pyrimidin-2-yl)-amino]phenyl}-methanesulfon-
amide (18). The majority of the newly synthesized compounds 
displayed potent anticancer activity, comparable to that of 
doxorubicin, on three human cancer cell lines, including the 
human breast adenocarcinoma cell line (MCF-7), cervical car-
cinoma cell line (HeLa) and colonic carcinoma cell line (HCT-
116). Compounds 18, 13b and 10 were nearly as active as doxo-
rubicin whereas compounds 6, 7b and 15 exhibited marked 
growth inhibition, but still lower than doxorubicin.
Keywords: thieno[3,2-d]pyrimidines, thienotriazolopyrimi-
dine derivatives, antitumor activity
HEND N. HAFEZ1,2 
ABDEL-RHMAN B. A. EL-GAZZAR1,2
1 Al-Imam Mohammad Ibn Saud 
Islamic University (IMSIU) 
Faculty of Science 
Department of Chemistry 
P. O. Box 90950, Riyadh 11623 
Kingdom of Saudi Arabia
2 Photochemistry Department 
(Heterocyclic & Nucleosides Unit) 

















Accepted October 12, 2017 
Published online October 30, 2017
* Correspondence; e-mail: profelgazzar@yahoo.com; abagazzar@imamu.edu.sa
528
H. N. Hafez and A.-R. B. A. El-Gazzar: Synthesis and evaluation of antitumor activity of new 4-substituted thieno[3,2-d]pyrimidine 
and thienotriazolopyrimidine derivatives, Acta Pharm. 67 (2017) 527–542.
 
Chemical study of pyrimidine nucleus plays an important role in the synthesis of a 
variety of fused heterocyclic compounds possessing a wide range of pharmacological ac-
tivity. Fused pyrimidines such as thienopyrimidines are a promising class of synthetic 
heterocyclic compounds with numerous biological activities (1–3), in particular antimicro-
bial (4, 5), antitumor (6, 7) and mitotic arrest of breast cancer (8).
Thieno[3,2-d]pyrimidine derivatives display a wide range of activities acting as anti-
convulsants (9), antivirals (10), antibiotics (11), antiglaucoma agents (12) and platelet ag-
gregation inhibitors (13). On the other hand, some 2-substituted-thieno[3,2-d]pyrimidine- 
-4-ones are considered to exert antihyperlipidemic (14) and anti-inflammatory activity (15). 
Also, 2-(phenylsulfonyl)methyl-thieno[3,2-d]pyrimidine derivatives act as novel HIV-1 
replication inhibitors (16). Further, benzo-thieno[3,2-d]pyrimidin-4-one sulphonamide 
thio-derivatives act as inhibitors of COX-2, iNOS and ICAM-1 (17). Thieno[3,2-d] pyrimi-
dine derivatives have recently become an important class of chemotherapeutic drugs, no-
tably for the treatment of cancers, such as PI3K inhibitor (18), PI3K and mTOR dual in-
hibitor (19). Therefore, thieno[3,2-d]pyrimidines and their derivatives have consistently 
attracted scientific interest and prompted us to develop and identify new molecules, in 
order to investigate the effect of structural modifications on their antitumor activities.
EXPERIMENTAL
Chemicals and equipment
All melting points were measured on an Electrothermal 9100 series digital melting 
point apparatus (Shimadzu, Japan). Microanalytical data were gathered with a Vario Ele-
mentar apparatus (Shimadzu). Elemental analyses of all compounds were within ± 0.4 % 
of the theoretical values. IR spectra (KBr) were recorded on a Perkin Elmer 1650 spectro-
meter (USA). 1H NMR and 13C NMR spectra were recorded on a JEOL EX-300 and a JEOL 
ECA-500 (Jeol, Japan). Chemical shifts were expressed in ppm relative to SiMe4 as internal 
standard in DMSO-d6 as a solvent. Mass spectra were recorded on a 70 eV Finnigan SSQ 
7000 spectrometer (Thermo-Instrument System Incorporation, USA). Purity of the com-
pounds was checked on aluminum plates coated with silica gel (Merck, Germany). Chemi-
cals and solvents (Analar ≥ 99 %) were purchased from Sigma-Aldrich (USA). 3-Amino- 
-5-phenyl-thiophene-2-methylcarboxylate was purchased from Sigma-Aldrich. Doxorubicin 
disks were supplied by the Pasteur Laboratory (Egypt).
Syntheses
3-Methyl-6-phenyl-2-thioxo-2H,3H-thieno[3,2-d]pyrimidin-4(1H)-one (2). – A mixture of 
3-amino-5-phenyl-thiophene-2-methylcarboxylate (0.1 mol) and methyl isothiocyanate 
(0.15 mol) was refluxed in dry dioxane (30 mL) under dry conditions for 8 h. The reaction 
mixture was then cooled to room temperature. The resulting mixture was poured onto 
water, stirred for 10 min and the aqueous part was filtered off. The solid product, methyl 
3-[(methylcarbamothioyl)amino]-5-phenylthiophene-2-carboxylate (1), was dissolved in 
NaOMe solution (30 mL, 20 %), stirred in a water bath for 2 h, allowed to cool to room 
temperature and neutralized with HCl. The solid formed was filtered off and crystallized 
from dioxane to give compound 2 as white powder.
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4-Chloro-3-methyl-6-phenyl-thieno[3,2-d]pyrimidine-2(3H)-thione (3). – A mixture of 2 
(0.005 mol), phosphorous oxychloride (0.1 mol) and N,N-dimethylamine (0.005 mol) was 
refluxed at 110 oC for 24 h. The reaction mixture was then cooled and the excess phospho-
ryl chloride was removed under reduced pressure. The resulting red oil was poured slow-
ly onto ice water (30 mL), stirred for 10 min and the aqueous part was extracted with 
EtOAc (10–25 mL). The combined organic layers were dried over Na2SO4, filtered, and the 
solvent was removed under reduced pressure to give an oily residue, which was purified 
by column chromatography (hexane/ethyl acetate, 1:1) (100 mL) to obtain a pale yellow 
solid.
3-Methyl-4-(substituted secondary amino/aminophenyl)-6-phenyl-thieno[3,2-d] pyrimidine-
2(3H)-thione (4a-c, 6 and 7a-c). General procedure. – To a warm solution of 3 (0.01 mol) in 
glacial acetic acid (40 mL), the freshly distilled secondary amine (namely morpholine, pi-
perazine, N-methylpiperazine) and aliphatic or aryl-amine (namely, ethanolamine, 4-ani-
sidine, 4-chloroaniline and 4-nitroaniline) (0.01 mol) were added. The reaction mixture 
was stirred under reflux for 3 h, then allowed to cool to 0 oC for 4–6 h, and the solid ob-
tained was filtered, washed with water (100 mL), dried and recrystallized from an appro-










(5). – A mixture of compound 3 (10 mmol), tributyl-(3,6-dihydro-2H-pyran-4-yl)stannane 
(10 mmol), bis-(triphenylphosphene) palladium(II) chloride (1.40 g, 2 mmol), triphenyl-
phosphine (10 mmol), lithium chloride (5 g, 117 mmol) and 2,6-di-tert-butyl-p-cresol (0.20 g, 
1 mmol) in dimethylformamide (DMF, 30 mL) was stirred under heating at 120 °C for 6 h. 
The reaction mixture was allowed to cool to room temperature and to concentrate. Flash 
chromatography (heptane/ethyl acetate, 9:1, then ethyl acetate) afforded compound 5 as 
pale yellow powder.
4-Hydrazinyl-3-methyl-6-phenyl-thieno[3,2-d]pyrimidine-2(3H)-thione (8). – Compound 3 
(0.01 mol) and hydrazine hydrate (99 %) (25 mL) were stirred under gentle reflux (70–80 °C) 
for 8 h; the reaction mixture was allowed to cool to room temperature. The solid formed 
was filtered off, washed with ethanol and dried. Yellow powder crystals obtained were 
recrystallized from DMF.
4-(Alkoxyphenoxy)-3-methyl-6-phenyl-thieno[3,2-d]pyrimidine-2(3H)-thione (9a,b). Gene-
ral method. – Freshly prepared dry sodium 3-methoxyphenolate and/or sodium 4-methoxy-
phenolate (1.75 g, 12 mmol) was added to a solution of 3 (5 mmol) in dry DMF (3 mL). The 
reaction mixture was stirred at room temperature for 4 h. Water was added to stop the 
reaction. The organic layer was washed with 2 mol L–1 NaOH, dried over MgSO4, filtered 
and the solution was concentrated under reduced pressure. The precipitate that was 
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formed was triturated with a mixture of petroleum ether/diethyl ether and filtered off. The 
following compounds were prepared: 4-(4-methoxyphenoxy)-3-methyl-6-phenyl-
thieno[3,2-d]pyrimidine-2(3H)-thione (9a) and 4-(3-methoxyphenoxy)-3-methyl-6-phenyl-
thieno[3,2-d]pyrimidine-2(3H)-thione (9b).
Ethyl[(3-methyl-6-phenyl-2-thioxo-2,3-dihydrothieno[3,2-d]pyrimidin-4-yl)-oxy]-acetate 
(10). – A mixture of 2 (0.01 mol) and ethyl chloroacetate (1.3 mL, 0.012 mol) in sodium eth-
oxide solution (0.46 g of sodium metal in 20 mL of absolute ethanol) was heated under re-
flux for 2 h. The solvent was acidified with cold diluted HCl (2 mol L–1, 20 mL). The ob-
tained oily residue was extracted with ethyl acetate (3 × 50 mL). The solid obtained after 
evaporation of the solvent was filtered off, dried and recrystallized from dioxane.
2-Hydrazinyl-3-methyl-6-phenyl-thieno[3,2-d]pyrimidin-4(3H)-one (11). – A mixture of 2 
(0.01 mol) and hydrazine hydrate (99 %) (25 mL) was stirred under gentle reflux. After 30 
min when the solid product started separating out, heating was continued for 12 h and the 
reaction mixture was allowed to cool to room temperature. The solid that separated was 




sulfanyl]-acetamides (13a-c). General procedure. – Compound 2 (0.01 mol) was added to warm 
ethanolic KOH solution (10 %, 30 mL), the heating was continued for 30 min and the mix-
ture was allowed to cool to room temperature. The respective halo-compound (0.012 mol), 
namely, methyl iodide, 2-chloro-N-phenylacetamide, 2-chloro-N-(4-chlorophenyl)-acet-
amide or 2-chloro-N-(4-methoxyphenyl)-acetamide, was added. The reaction mixture was 
stirred under reflux for 7 h, then cooled to room temperature and poured into cold water 
(100 mL). The solid product which precipitated was filtered off, washed with 100 mL water, 
dried and crystallized to produce 12 and 13a-c. The following compounds were prepared: 
3-methyl-2-(methylsulfanyl)-6-phenyl-thieno[3,2-d]pyrimidin-4(3H)-one (12), 2-[(3-methyl- 
-4-oxo-6-phenyl-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)-sulfanyl]-N-phenyl-acetamide 
(13a), N-(4-chlorophenyl)-2-[(3-methyl-4-oxo-6-phenyle-3,4-dihydrothieno[3,2-d]pyrimi-
din-2-yl)sulfanyl]-acetamide (13b) and N-(4-methoxyphenyl)-2-[(3-methyl-4-oxo-6-phe-
nyl-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-acetamide (13c).
4-Methyl-1,7-diphenyl-thieno[2,3-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-one (14). – To a 
mixture of 12 (0.01 mol) and benzohydrazide (0.01 mol) in dioxane (30 mL), a catalytic 
amount of piperidine was added. The reaction mixture was stirred under reflux for 12 h, 
allowed to cool to room temperature and poured into water (100 mL). The deposited pre-
cipitate was filtered off, dried and crystallized from dioxane. The compound was obtained 
as green powder.
1-Amino-4-methyl-7-phenyl-thieno[2,3-e][1,2,4]triazolo[4,3-a]pyrimidin-5(4H)-one (15). – 
To a mixture of 12 (0.01 mol) and thiosemicarbazide (0.01 mol) in dioxane (30 mL), a cata-
lytic amount of piperidine was added. The reaction mixture was stirred under reflux for 
12 h, allowed to cool to room temperature and poured into water (100 mL). The solid 
product was filtered off, dried and crystallized from dioxane. Compound 15 was obtained 
as yellow powder.
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3-Methyl-2-(methylsulfonyl)-6-phenyl-thieno[3,2-d]pyrimidin-4(3H)-one (16). – A mixture 
of 12 (0.01 mol) and an excess amount of hydrogen peroxide (5 mL) in acetic acid (30 mL) 
was heated gently under stirring for 10 h. The reaction mixture was allowed to cool to 0 °C. 
The deposited precipitate was filtered off and crystallized from dioxane.
2-[(4-Aminophenyl)-amino]-3-methyl-6-phenyl-thieno[3,2-d]pyrimidin-4(3H)-one (17). – To 
a warm solution of 16 (0.01 mol) in glacial acetic acid (40 mL), 4-phenylenediamine (0.01 
mol) was added. The reaction mixture was stirred under reflux for 4 h, then allowed to cool 
to 0 oC for 4-6 h, and the solid obtained was filtered, washed with water (100 mL), dried 
and recrystallized from DMF to produce 17 as yellow crystals.
N-{4-[(3-methyl-4-oxo-6-phenyl-3H,4H-thieno[3,2-d]pyrimidin-2-yl)-amino]phenyl}-meth-
anesulfonamide (18). – To a solution of amino compound 17 (1.0 mmol) in pyridine (5 mL), 
methanesulfonyl chloride (1.50 mmol) was added and the mixture was heated under reflux 
for 12 h. Under reduced pressure, the solvent was removed and the crude residue was ex-
tracted with EtOAC and washed with diluted HCl. The organic layer was dried over 
MgSO4. The crude residue was purified by flash chromatography on silica gel, dried and 
recrystallized from ethanol to produce 18 as brown crystals.
Biological screening
In vitro anticancer activity. – We evaluated the activity of compounds 2-11, 13-16 and 
18 against the human breast adenocarcinoma cell line (MCF-7), human cervical carcinoma 
cell line (HeLa) and human colonic carcinoma cell line (HCT-116) using the sulforhoda-
mine B assay (20). The three human cancer cell lines were provided by the National Cancer 
Institute (NCI, Cairo, Egypt). Continuous drug exposure for 48 h was the method used. All 
the cell lines were cultured in Dulbecco’s modified Eagle’s medium containing 10 % fetal 
bovine serum (FBS) (in a humidified atmosphere with 5 % CO2 at 37 °C). Their growth as 
a monolayer was maintained in RPMI-1640 medium supplemented with 5 % heat inacti-
vated FBS, 2 mmol L–1 glutamine and antibiotics (penicillin 100 U mL–1, streptomycin 100 
μg mL–1). The effect of compounds on the in vitro growth of human tumor cell lines was 
evaluated using sulforhodamine B (SRB) as protein binding dye to assess cell growth. Cells 
growing in 96-well plates were obtained by plating 1.5 × 105 cells mL–1. The microtiter 
plates were incubated at 37 °C for 24 h prior to addition of experimental drugs and were 
incubated for 48 h with five different concentrations of each compound (0.01, 0.1, 1, 10, 100 
μg mL–1), which were dissolved in DMSO and diluted with saline to the mentioned con-
centration, starting from a maximum concentration of 100 μg mL–1. After 48 h, the cell 
monolayers were fixed by addition of 10 % (m/V) trichloroacetic acid and incubated at 4 °C 
for 1 h, and then stained for 30 min with 0.4 % (m/V) sulforhodamine B in 1 % acetic acid. 
Excess of unbound dye was removed by four washes with 1 % acetic acid and the attached 
stain was recovered with Tris-EDTA buffer. Absorbance was measured and growth inhibi-
tion of 50 % (GI50) was calculated (21). Table III displays GI50 values of each compound for 
the above listed three cell lines. Doxorubicin was used as a reference compound.
The influence of solvent, DMSO, on the growth of cell lines was evaluated in all ex-
periments (negative control). This was performed by exposing untreated control cells to 
the maximum concentration of DMSO used in each assay (0.5 %).
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The reaction sequence employed for the synthesis of 3-methyl-6-phenyl-2-thioxo-2,3-
dihydrothieno[3,2-d]pyrimidin-4(1H)-one (2) is outlined in Scheme 1. Initially, the reaction 
Scheme 1.
of 3-amino-5-phenyl-thiophene-2-methylcarboxylate with methyl isothiocyanate afforded 
methyl-3-[(methylcarbamothioyl)amino]-5-phenylthiophene-2-carboxylate (1) as an inter-
mediate, which underwent cyclization under basic conditions (22) to form the target com-
pound 2. The structure of 2 was confirmed by spectral data.
Introduction of halogen on fused pyrimidine nucleus is primarily used to generate 
4-chloro-3-methyl-6-phenyl-thieno[3,2-d]pyrimidine-2(3H)-thione (3), which is the key in-
termediate for the formation of a variety of thieno[3,2-d]pyrimidine derivatives (4–7, 9, 10). 
4-Chloro-3-methyl-6-phenyl-thieno[3,2-d]pyrimidine-2(3H)-thione (3) was prepared by the 
treatment of 3-methyl-6-phenyl-2-thioxo-2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-one (2) 
with phosphorous oxychloride under dry conditions (dioxane), which was then converted 
to the corresponding 4-amino derivatives (4a-c) with morpholine, piperazine and N-meth-
yl piperazine. Besides correct values of elemental analyses, IR, NMR and mass spectra of 
compounds 4a-c are in agreement with the assigned structures (Tables I and II). IR spec-
trum of 4b shows C=N at 1600 cm–1 and the broad absorption band at 3365 cm–1 for NH. 1H 
NMR spectra showed singlet NCH3 at δ 3.13 ppm, multiplet signals for 4 CH2 at δ 2.65 to 
3.38 ppm, singlet signal for the thiophene proton at δ 8.01 ppm and multiplet signals at δ 
6.96-7.05 (m, 2H, Ar-H) and 7.45-7.53 (m, 3H, Ar-H) for phenyl. Moreover, the broad absorp-
tion signal for the NH group at δ 9.60 ppm was observed. The mass spectrum showed m/z 
342 corresponding to the molecular ion peak [M]+ and m/z 343 [M+1]+.
Reactivity of chlorine in the pyrimidine moiety of compound 3 was responsible for 
getting the coupling product 5 in the presence of tributyl(3,6-dihydro-2H-pyran-4-yl) stan-
nane.
4-[(2-Hydroxyethyl)amino- and 4-methoxy/4-chloro- and/or 4-nitro-phenylamino]-
3-methyl-6-phenyl-thieno[3,2-d]pyrimidine-2(3H)-thione (6, 7a-c) were prepared by a sub-
stitution reaction of compound 3 with amine derivatives, namely, ethanolamine, 4-me-
thoxy-aniline, 4-chloroaniline and 4-nitroaniline in absolute ethanol. Treatment of 
compound 3 with hydrazine hydrate gave the 4-hydrazino derivative (8), and treatment of 
4-chloro-3-methyl-6-phenyl-thieno[3,2-d]pyrimidine-2(3H)-thione (3) with 3-methoxyphe-
nol and 4-methoxyphenol in the presence of K2CO3 in DMF at 25 °C for 6 h afforded 
4-(alkoxyphenoxy)-3-methyl-6-phenyl-thieno[3,2-d]pyrimidine-2(3H)-thione derivatives 
(9a,b). Moreover, treatment of 3-methyl-6-phenyl-2-thioxo-2,3-dihydrothieno[3,2-d]pyrimi-
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Table I. Physical and analytical data of newly synthesized compounds


























4b C17H18N4S2 (342.48) 215-217 79
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din-4(1H)-one (2) with ethyl chloroacetate yielded ethyl[(3-methyl-6-phenyl-2-thioxo-2,3-
dihydrothieno[3,2-d]pyrimidin-4-yl)-oxy]acetate (10) in good yield (Scheme 2).
On the other hand, the reaction of compound 2 with hydrazine hydrate in refluxing 
ethanol afforded the 2-hydrazino derivative 11. Formation of 2-hydrazino derivative 11 pro-
ceeded via loss of 1 mol of H2S. 3-Methyl-2-(methylsulfanyl)-6-phenyl-thieno[3,2-d]pyrimi-
din-4(3H)-one (12) and N-(phenyl/substituted-phenyl)-2-[(3-methyl-4-oxo-6-phenyle-3,4-
dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-acetamides (13a-c) were prepared in good 
yield via the one pot reaction of 3-methyl-6-phenyl-2-thioxo-2,3-dihydrothieno[3,2-d]pyrim-
idin-4(1H)-one (2) with methyl-iodide and/or 2-chloro-N-substituted phenyl-(4-
chloropenyl/4-methoxyphenyl)-acetamide derivatives. Also, the reaction of compound 12 
with benzoylhydrazine and/or thiosemicarbazide afforded 4-methyl-(1-phenyl/ or amino)-
7-phenyl-thieno[2,3-e][1,2,4]-triazolo[4,3-a]pyrimidin-5(4H)-one derivatives (14, 15) (Scheme 
3). The 1H NMR spectra of compounds 14 and 15 revealed the absence of SCH3 and the ap-
pearance of the phenyl ring as multiplet absorption signals around δ 7.41-7.57 ppm for com-
pound 14. Moreover, a broad absorption signal for the NH2 group at δ 9.20 ppm was re-
corded for compound 15 (Table II).
Further, treatment of compound 12 with hydrogen peroxide in acetic acid afforded 
sulfonyl derivative 16, which is a key intermediate for the synthesis of 2-[(4-amino-phenyl)-
amino]-3-methyl-6-phenyl-thieno[3,2-d]pyrimidin-4(3H)-one (17), in good yield by the 
treatment of a warm solution of compound 16 and 4-phenylenediamine in glacial acetic 
acid. Finally, 2-arylamino-thieno[3,2-d]-pyrimidine derivative 17 was refluxed with metha-
nesulfonyl chloride in pyridine to afford N-{4-[(3-methyl-4-oxo-6-phenyl-3,4-dihydro-
thieno[3,2-d]pyrimidin-2-yl)amino]-phenyl}-methane-sulfonamide (18).
Postulated structures of the newly synthesized compounds 16, 17 and 18 are in agree-
ment with their IR, NMR spectral and elemental analysis data (Tables I, II). The 1H NMR 
Scheme 2.
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spectrum of 17, for example, showed a singlet signal at δ 2.92 ppm corresponding to NCH3. 
It also showed the aromatic protons at δ 6.92-7.11 (m, 2H, phenyl), 7.25 (d, 2H, J = 8.38 Hz, 
phenyl), 7.37-7.45 (m, 3H, phenyl), 7.85 (d, 2H, J = 8.40 Hz, phenyl), 8.13 (s, CH thiophene) and 
two broad bands corresponding to 2 NH at δ 9.35, 9.85 ppm, which were D2O exchangeable.
Antitumor activity and structure activity relationship
Most of the newly synthesized compounds were evaluated for their in vitro anticancer 
activity against the human breast adenocarcinoma cell line (MCF-7), cervical carcinoma 
Table III. Effects of synthesized compounds on the growth of the human breast adenocarcinoma cell line 




2 29.13 ± 5.97 23.44 ± 7.58 20.57 ± 1.89
3 12.86 ± 1.51 15.09 ± 3.71 17.09 ± 2.3
4a 9.26 ± 3.27 12.23 ± 1.10 15.09 ± 3.71
4b 7.24 ± 2.34 10.20 ± 2.05 12.07 ± 1.89
4c 10.86 ± 1.53 12.80 ± 2.51 15.25 ± 2.78
5 18.54 ± 1.35 20.16 ± 1.34 20.60 ± 4.20
6 2.26 ± 0.94 2.95 ± 0.74 4.36 ± 0.82
7a 15.87 ± 1.70 20.16 ± 1.20 20.56 ± 1.72
7b 2.48 ± 0.93 1.49 ± 0.81 2.67 ± 0.38
8 17.09 ± 2.4 15.22 ± 1.43 12.87 ± 1.31
9a 25.44 ± 8.67 42.28 ± 2.98 88.96 ± 12.06
9b 8.58 ± 3.90 4.70 ± 0.49 20.68 ± 3.09
10 0.81 ± 0.26 0.55 ± 0.03 1.01 ± 0.52
11 10.80 ±1.50 9.80 ± 1.08 8.50 ± 2.01
13a 21.48 ± 0.74 44.72 ± 2.19 16.54 ± 1.02
13b 0.70 ± 0.47 0.46 ± 0.42 88.62 ± 10.06
13c 4.90 ± 0.68 5.92 ± 2.01 22.18 ± 4.63
14 7.36 ± 1.63 10.53 ± 1.08 8.05 ± 2.04
15 1.06 ± 0.51 1.80 ± 0.59 5.37 ± 2.40
16 6.27 ± 0.72 23.45 ± 5.85 15.75 ± 1.82
18 0.09 ± 0.005 0.38 ± 0.02 1.07 ± 0.67
Doxorubicin 0.05 ± 0.009 0.35 ± 0.03 0.65 ± 0.05
GI50 – concentrations that cause 50 % cell growth inhibition after continuous exposure for 48 h.
Mean ± SEM of three independent experiments performed in duplicate.
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cell line (HeLa) and colonic carcinoma cell line (HCT-116). As shown in Table III, it was 
found that thieno[3,2-d]pyrimidine bearing benzene methyl sulphonamide (18) was nearly 
as active as doxorubicin with respective GI50 values of 0.09, 0.38 and 1.07 μmol L–1 vs. 0.05, 
0.35 and 0.65 μmol L–1, resp. Dihydrothieno[3,2-d]pyrimidinyl)-sulfanyl]-acetamide (13b) 
with GI50 values of 0.70 and 0.46 μmol L–1 was fairly active against the human breast adeno-
carcinoma cell line (MCF-7) and active as doxorubicin against the cervical carcinoma cell 
line (HeLa), resp., but had low inhibition activity against the colonic carcinoma cell line 
(HCT-116). Also, ethyl[(3-methyl-6-phenyl-2-thioxo-2,3-dihydrothieno[3,2-d]pyrimidin-
4-yl)-oxy]acetate (10), with GI50 values of 0.81, 0.55 and 1.01 μmol L–1, was of comparable 
activity to doxorubicin against HeLa; this may be attributed to the presence of ether link-
age. However, compound 15 with GI50 values of 1.06, 1.80 and 5.37 μmol L–1 also exhibited 
reasonable activities against the breast adenocarcinoma cell line (MCF-7) and cervical car-
cinoma cell line (HeLa) but modest activity against the colonic carcinoma cell line (HCT-
116), which was probably due to the presence of aminotriazolo attached to the pyrimidine 
moiety. However, with a phenyl-triazolo moiety in compound 14, it retained some inhibi-
tion activity. Compound 7 with GI50 values of 2.26, 2.95 and 4.36 μmol L–1 exhibited moder-
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4-Cl in compound 3 by the phenylamine moiety increased the growth inhibitory effect in 
compound 7b but decreased growth inhibition in compound 7a. Increase in the activity of 
7b may be attributed to the presence of the 4-Cl substituent in the phenyl ring (electron 
withdrawing group), while the presence of the 4-OCH3 substituent in the phenyl ring 
(electron donating group) decreased the growth inhibition activity of 7a. When comparing 
4-chlorothieno[3,2-d] pyrimidine derivatives, it was found that compound 3 was more ef-
fective than compound 2 due to the presence of chlorine instead of carbonyl group. On the 
other hand, replacement of 4-Cl in compound 3 by six-member heterocyclic groups con-
taining oxygen and nitrogen (namely, morpholine, piperazine and methyl piperazine) led 
to increased growth inhibition in the case of 4a-c. Nevertheless, 4a-c still exhibited modest 
growth inhibition activity in comparison with doxorubicin. However, replacement of chlo-
rine in compound 3 by a pyrane ring decreased the growth inhibition, like in the case of 
compound 5. Compounds 9b, 11 and 13c showed modest inhibition activities towards the 
human breast adenocarcinoma cell line (MCF-7) and cervical carcinoma cell line (HeLa), 
while compound 16 had modest activity towards MCF-7 but low inhibition towards HeLa 
and HCT-116. Finally, compounds 2, 9a, 13a exerted low inhibition activities towards all 
the three tumor cell lines.
CONCLUSIONS
Novel thieno[3,2-d]pyrimidine derivatives were synthesized and evaluated for their 
anticancer activity. N-{4-[(3-methyl-4-oxo-6-phenyl-3H,4H-thieno[3,2-d]pyrimidin-2-yl)-
amino]phenyl}-methanesulfonamide (18), N-(4-chlorophenyl)-2-[(3-methyl-4-oxo-6-phe-
nyl-3,4-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-acetamide (13b) and ethyl[(3-methyl-
6-phenyl-2-thioxo-2,3-dihydrothieno[3,2-d]pyrimidin-4-yl)-oxy]acetate (10) were nearly as 
active as doxorubicin against the three tumor cell lines, MCF-7, HeLa and HCT-116.
Acknowledgements. – The authors are grateful to the Micro-analytical Unit, Cairo University, 
Egypt, for micro-analytical data, IR, NMR and mass spectra. The authors are also grateful to the staff 
of the Antitumor Laboratory, at the National Cancer Institute, Cairo University, Egypt. The authors 
extend their sincere appreciation to the Deanship of Scientific Research at the Al-Imam Mohammad 
Ibn Saud Islamic University for its funding of this research through the Research Group Project no. 
341212.
REFERENCES
 1.  P. Mukherjee, H. Sevrioukova, I. Li, G. Chreifi, P. Martásek, L. J. Roman, T. L. Poulos and R. B. 
Silverman, Novel 2,4-disubstituted pyrimidines as potent, selective, and cell-permeable inhibi-
tors of neuronal nitric oxide synthase, J. Med. Chem. 58 (2015) 1067–1088; https://doi.org/10.1021/
jm501719e
 2.  H. N. Hafez, H. A. R. Hussein and A. B. A. El-Gazzar, Synthesis of substituted thieno [2,3-d]py-
rimidine-2,4-dithiones and their S-glycoside analogues as potential antiviral and antibacterial 
agents, Eur. J. Med. Chem. 45 (2010) 4026–4034; https://doi.org/ 10.1016/j.ejmech.2010.05.060
 3.  H. N. Hafez and A. B. A. El-Gazzar, Design and synthesis of 3-pyrazolyl-thiophene, thieno[2,3-d]
pyrimidines as new bioactive and pharmacological activities, Bioorg. Med. Chem. Lett. 18 (2008) 
5222–5227; https://doi.org/10.1016/j.bmcl.2008.08.071
541
H. N. Hafez and A.-R. B. A. El-Gazzar: Synthesis and evaluation of antitumor activity of new 4-substituted thieno[3,2-d]pyrimidine 
and thienotriazolopyrimidine derivatives, Acta Pharm. 67 (2017) 527–542.
 
 4.  H. M. Aly, N. M. Saleh and H. A. Elhady, Design and synthesis of some new thiophene, thienopy-
rimidine and thienothiadiazine derivatives of antipyrine as potential antimicrobial agents, Eur. 
J. Med. Chem. 46 (2011) 4566–4572; doi: 10.1016/j.ejmech.2011.07.035
 5.  H. N. Hafez, A. B. A. El-Gazzar and M. E. A. Zaki, Simple approach to thieno[3,2-d]-pyrimidines 
as new scaffolds of antimicrobial activities, Acta Pharm. 66 (2016) 331–351; https://doi.org/10.1515/
acph-2016-0029
 6.  W. F. Zhu, X. Zhai, S Li, Y. Cao, P. Gong and Y. J. Liu, Synthesis and cytotoxic activity of novel 
2,6-disubstituted-4-morpholino-thieno[3,2-d]pyrimidines as potent anti-tumor agents, Chin. 
Chem. Lett. 23 (2012) 703–706; https://doi.org/10.1016/j.cclet.2012.04.012
 7.  Z. Liu, S. Wu, Y. Wang, R. Li, J. Wang, L. Wang, Y. Zhao and P. Gong, Design, synthesis and bio-
logical evaluation of novel thieno[3,2-d]pyrimidine derivatives possessing diaryl semicarbazone 
scaffolds as potent antitumor agents, Eur. J. Med. Chem. 87 (2014) 782–793; https://doi.org/10.1016/j.
ejmech.2014.10.022
 8.  C. R. Ross, K. W. Temburnikar, G. M. Wilson and K. L. Seley-Radtke, Mitotic arrest of breast can-
cer MDA-MB-231 cells by halogenated thieno[3,2-d]pyrimidines, Bioorg. Med. Chem. Lett. 25 (2015) 
1715–1717; https://doi.org/10.1016/j.bmcl.2015.02.071
 9.  S. N. Sirakanyan, E. K. Akopyan, R. G. Paronikyan, A. G. Akopyan and A. A. Ovakimyan, Syn-
thesis and anticonvulsant activity of 7(8)-amino derivatives of condensed thieno[3,2-d]pyrimi-
dines, Pharm. Chem. J. 50 (2016) 296–300; https://doi.org/10.1007/s11094-016-1439-5
10.  H. N. Hafez, H. A. R. Hussein and A. B. A. El-Gazzar, Synthesis of substituted thieno[2,3-d]py-
rimidine-2,4-dithiones and their S-glycoside analogues as potential antiviral and antibacterial 
agents, Eur. J. Med. Chem. 45 (2010) 4026–4034; https://doi.org/10.1016/j.ejmech.2010.05.060
11.  S. Kukolja, S. E. Draheim, B. J. Graves, D. C. Hunden, J. L. Pfeil, R. D. G. Cooper, J. L. Ot and F. T. 
Couter, Orally absorbable cephalosporin antibiotics. 2. Structure-activity studies of bicyclic gly-
cine derivatives of 7-aminodeacetoxycephalosporanic acid, J. Med. Chem. 28 (1985) 1896–1903; 
https://doi.org/10.1021/jm00150a023
12.  J. D. Prugh, G. D. Hartman, P. J. Mallorga, B. M. McKeever, S. R. Michelson, M. A. Murcko, H. 
Schwam, R. L. Smith, J. M. Sondey, J. P. Springer and M. F. Surgrue, New isomeric classes of topi-
cally active ocular hypotensive carbonic anhydrase inhibitors: 5-substituted thieno[2,3-b]thio-
phene-2-sulfonamides and 5-substituted thieno[3,2-b]thiophene-2-sulfonamides, J. Med. Chem. 34 
(1991) 1805–1818; https://doi.org/10.1021/ jm00110a008
13.  M. S. Egbertson, J. J. Cook, B. Bednar, J. D. Prugh, R. A. Bednar, S. L. Gaul, R. J. Gould, G. D. Hart-
man, C. F. Homnick, M. A. Holahan, L. A. Libby, J. J. Lynch Jr., R. J. Lynch, G. R. Sitko, M. T. Stra-
nieri and L. M. Vassallo, Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained -thienothio-
phene α-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregation, J. Med. 
Chem. 42 (1999) 2409–2421; https://doi.org/10.1021/jm980722p
14.  R. S. Tamboli, R. D. Amrutkar, K. S. Jain and M. K. Kathiravan, Synthesis and in vivo  a n t i h y -
perlipidemic potential of novel substituted thieno[3,2-d]pyrimidines, Lett. Drug Des. Discov. 10 
(2013) 906–915; https://doi.org/10.2174/15701808113109990019
15.  Y. Endo, K. Kawai, T. Asano, S. Amano, Y. Asanuma, K. Sawada, Y. Onodera, N. Ueo, N. Taka-
hashi, Y. Sonoda, N. Kamei and T. Irie, 2-(Isopropylamino)-thieno[3,2-d]-pyrimidin-4(3H)-one 
derivatives as selective phosphodiesterase 7 inhibitors with potent in vivo efficacy, Bioorg. Med. 
Chem. Lett. 25 (2015) 1910–1914; https://doi.org/10.1016/ j.bmcl.2015.03.031
16.  J. Kim, J. Kwon, D. Lee, S. Jo, D. S. Park, J. Choi, E. Park, J. Y. Hwang, Y. Ko, I. Choi, M. K. Ju, J. Ahn, 
J. Kim, S. J. Han, T. H. Kim, J. Cechetto, J. Nam, S. Ahn, P. Sommer, M. Liuzzi and J. Lee, Seren-
dipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel 
HIV-1 replication inhibitors, Bioorg. Med. Chem Lett. 24 (2014) 5473–5477; https://doi.org/10.1016/j.
bmcl.2014.10.007
542
H. N. Hafez and A.-R. B. A. El-Gazzar: Synthesis and evaluation of antitumor activity of new 4-substituted thieno[3,2-d]pyrimidine 
and thienotriazolopyrimidine derivatives, Acta Pharm. 67 (2017) 527–542.
 
17.  M. Barone, G. Pannuzzo, A. Santagati, A. Catalfo, G. De Guidi and V. Cardile, Molecular docking 
and fluorescence characterization of benzothieno[3,2-d]pyrimidin-4-one sulphonamide thio-de-
rivatives, a novel class of selective cyclooxygenase-2 inhibitors, Molecules 19 (2014) 6106–6122; 
https://doi.org/10.3390/molecules19056106
18.  Y. Ni, A. Gopalsamy, D. Cole, Y. Hu, R. Denny, M. Ipek, J. Liu, J. Lee, J. P. Hall, M. Luong, J. B. Telliez 
and L. L. Lin, Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase 
inhibitors, Bioorg. Med. Chem. Lett. 21 (2011) 5952–5956; https://doi.org/10.1016/j.bmcl.2011.07.069
19.  T. P. Heffron, M. Berry, G. Castanedo, C. Chang, I. Chuckowree, J. Dotson, A. Folkes, J. Gunzner, 
J. D. Lesnick, C. Lewis, S. Mathieu, J. Nonomiya, A. Olivero, J. Pang, D. Peterson, L. Salphati, D. 
Sampath, S. Sideris, D. P. Sutherlin, V. Tsui, N. C. Wan, S. Wang, S. Wong and B. Y. Zhu, Identifica-
tion of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor, Bioorg. Med. Chem. Lett. 20 
(2010) 2408–2411; https://doi.org/10.1016/ j.bmcl. 2010.03.046
20.  P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. T. Warren, H. Bokesch, S. 
Kenny and M. R. Boyd, New colorimetric cytotoxicity assay for anti-cancer drug screening, J. Natl. 
Cancer Inst. 82 (1990) 1107–1112; https://doi.org/10.1093/jnci /82.13.1107
21.  A. Monks, D. Scudiero, P. Skehan, R. Shoemaker, K. Paul, D. Vistica, C. Hose, J. Langley, P. Cronise, 
A. Vaigro-Wolff, M. Gray-Goodrich, H. Campbell, J. Mayo and J. M. Boyd, Feasibility of a high-flux 
anticancer drug screen using a diverse panel of cultured human tumor cell lines, J. Natl. Cancer 
Inst. 83 (1991) 757–766; https://doi.org/10.1093/ jnci /83.11.757
22.  A. S. Shestakov, M. A. Prezent, V. G. Kartsev and K. S. Shikhaliev, Synthesis of thieno[3,2-d]py-
rimidin-4-ones and alkylation thereof, Eur. Chem. Bull. 7 (2014) 713–718; https://doi.org/10.17628/
ECB.2014.3.713
